The effect of dose form on the bioavailability of mebendazole in man.
Open Access
- 1 January 1985
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 19 (1) , 87-90
- https://doi.org/10.1111/j.1365-2125.1985.tb02617.x
Abstract
Four different dose forms of mebendazole were administered to human volunteers, and urine was collected and assayed for mebendazole and unconjugated metabolites of mebendazole. Oral administration of mebendazole as an oily suspension slightly enhances the bioavailability of the drug, however mebendazole is not absorbed following rectal administration. The major urinary metabolite of mebendazole in humans is 2-amino-5(6)[alpha-hydroxybenzyl]benzimidazole (IV), not 2-amino- 5(6) benzoylbenzimidazole (II), as previously reported.This publication has 8 references indexed in Scilit:
- The effect of dose form on the bioavailability of mebendazole in man.British Journal of Clinical Pharmacology, 1985
- The pharmacokinetics and bioavailability of a tracer dose of [3H]‐ mebendazole in man.British Journal of Clinical Pharmacology, 1985
- 4-A mino-3-( 3′-methoxycarbonyl-2′-thioureido)benzophenone, a prodrug of mebendazoleEuropean Journal of Drug Metabolism and Pharmacokinetics, 1983
- Bioavailability and tolerability of mebendazole in patients with inoperable hydatid diseaseTransactions of the Royal Society of Tropical Medicine and Hygiene, 1982
- Chemotherapy of alveolar echinococcosisEuropean Journal of Clinical Pharmacology, 1981
- Plasma concentrations of mebendazole during treatment of echinococcosisEuropean Journal of Clinical Pharmacology, 1980
- Mebendazole in Enterobiasis Radiochemical and Pilot Clinical Study in 1,278 SubjectsJAMA, 1971